In the past decade there has been a growing interest in understanding sex and gender
differences in myocarditis and dilated cardiomyopathy (DCM), and the purpose of this review …

In modern cardiology, sodium‐glucose cotransporter 2 (SGLT2) inhibitors are critical
components of heart failure (HF) treatment algorithms and exert their effects primarily by …

Background: Sodium-glucose cotransporter-2 inhibitors have emerged as a key
pharmacotherapy in heart failure (HF) with both reduced and preserved ejection fraction …

Aims Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) improve clinical outcomes in heart
failure patients with reduced and preserved left ventricular ejection fraction (LVEF), but have …

Type 2 diabetes mellitus (T2DM) is highly prevalent and associated with a two-fold
increased mortality, mostly explained by cardiovascular diseases. Trial evidence on older …

Background: Women and men with heart failure (HF) and preserved ejection fraction may
differ in their clinical characteristics and their response to therapy. The aim of this study was …

Type 2 diabetes is one of the most relevant risk factors for heart failure, the prevalence of
which is increasing worldwide. The aim of the review is to highlight the current perspectives …

Importance Sodium glucose cotransporter 2 inhibitors reduce morbidity and mortality in
patients with heart failure and reduced ejection fraction (HFrEF). Clinicians may find …

Pathological sodium-water retention or edema/congestion is a primary cause of heart failure
(HF) decompensation, clinical symptoms, hospitalization, reduced quality of life, and …

Heart failure (HF) is associated with a high morbidity and mortality burden. In light of more
recent evidence, SGLT2 inhibitors are currently recommended as first-line therapy in …